Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 153

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 4
Chunk 153
---
 are used to transport material
with extremely low levels of radioactivity, and do not require special handling or protective gear in transit, or they can be shipped
in Type A Packages, which are commonly used for shipping intermediate amounts of radioactive material. Prior to shipment, our clinical
operations team ensures that all relevant clinicians undergo sufficient training as to proper handling, storage, and disposal of the Alpha
DaRT sources.

Our Marketing and Commercialization Strategies

We have yet to commercialize
in any geographical market, even though we presently have received marketing approval in Israel for the treatment of squamous cell carcinoma
of the skin or oral cavity using the Alpha DaRT, and expect that our existing clinical trials, if completed successfully, may be sufficient
to satisfy the regulatory requirements for marketing authorization in the United States, Europe and Japan. As we believe that the Alpha
DaRT technology has the potential address the majority of solid tumors, including in potential combination with immunotherapies, we are
focused on evaluating that potential in these various tumors by conducting clinical trials across multiple indications, to be incorporated
into a future plan of commercial launch, sequencing and pricing if we obtain marketing authorization(s) in the future. We aim to generate
clinical and healthcare economic data to support marketing authorization and third-party payor coverage and reimbursement in the United
States, which we see as our primary market, and we anticipate seeking to commercialize initially in the United States before other markets,
including Israel, notwithstanding our existing marketing approval in Israel.

We also believe that our clinical
trials being conducted in leading sites around the world will ultimately serve our commercial purposes as well, as we believe those clinical
sites may ultimately become lead commercial end-users or centers of excellence in the commercial setting.

While we ultimately envision
leading much of the commercialization of the Alpha DaRT in core markets such as the United States, we may choose to enter into distribution
agreements in other geographies with parties who have exemplary local sales and marketing capabilities. To that end, we have entered into
binding term sheets with Medison Pharma Ltd., one of the largest commercial partners of leading global biotech companies in international
markets, and its affiliates, to lead the potential commercialization of the Alpha DaRT in Canada and Israel. We intend to enter into definitive
commercial agreements covering the commercialization, distribution and sales of the Company’s future products in Canada and Israel.
Under these term sheets, effective for a 15-year term following the approval to sell our products, Medison will be responsible